Abstract: The invention relates to a device for cutting tubing, comprising a frame having an entry window and an exit window for defining a pathway of the longitudinal axis of the tube through the device, a cutting element arranged on the frame, wherein the cutting element is arranged lateral and opposite to the pathway of the tubing and wherein at least the portion of the frame is formed mobile and the cutting element is arranged on or opposite to the mobile portion to enable the cutting element to be pressed into the pathway of the longitudinal axis of the tubing.
Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
Abstract: A manually actuated drug-injecting device is configured such that the grip strength of the entire hand (i.e., majority of fingers closing toward the palm or heel of the hand) is employed to discharge medication through a hypodermic needle and into a patient's body. The device is well suited for delivering medications with high viscosity and/or by patients (e.g., elderly patients) with reduced finger strength and dexterity. The device includes a grip member, a push member (which causes the medication to be injected), and a force-transfer mechanism that couples the grip member to the push member. Suitably, the device is configured to be held transverse to the palm of the medication-administering hand, with a discharge port located by the outer, blade edge of the administering hand, when the device is being gripped to administer medication.
Type:
Grant
Filed:
November 20, 2017
Date of Patent:
November 16, 2021
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Peter A. Basile, Henry J. Mack, Jr., Oliver Sha, Stephen G. Miggels
Abstract: The present invention relates to 2,3-dihydrobenzothiophene derivatives of the general formula I In which the occurring groups and parameters have the meanings indicated in claim 1, to the use thereof in liquid-crystalline or mesogenic media, to liquid-crystalline or mesogenic media comprising these derivatives, and to electro-optical display elements containing these liquid-crystalline or mesogenic media.
Type:
Grant
Filed:
June 25, 2018
Date of Patent:
November 16, 2021
Assignee:
MERCK PATENT GMBH
Inventors:
Dmitry Ushakov, Helga Haas, Thorsten Vom Stein
Abstract: The present invention is directed to substituted certain reversed indazole compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1A, R1B, X, Y, RZ and R2 are as defined herein, which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
Type:
Grant
Filed:
October 8, 2018
Date of Patent:
November 16, 2021
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
John Acton, David Annunziato Candito, J. Michael Ellis, Peter H. Fuller, Hakan Gunaydin, Blair T. Lapointe, Weiguo Liu, Joey L. Methot, Santhosh F. Neelamkavil, Barbara Pio, Vladimir Simov, Harold B. Wood
Abstract: An optically active structure and a display device are presented. The device utilized an optically active structure comprising liquid crystal material and a plurality of nanorods configured to emit light in one or more predetermined ranges in response to pumping light. Variation in orientation of the liquid crystal varies orientation of the nanorods and modulated light emission therefrom.
Type:
Grant
Filed:
September 20, 2015
Date of Patent:
November 16, 2021
Assignees:
Yissum Research Development Company Of The Hebrew
University of Jerusalem Ltd., Merck Patent GmbH
Inventors:
Uri Banin, Hagai Arbell, Bernhard Rieger, Ming-Chou Wu
Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.
Type:
Grant
Filed:
February 20, 2020
Date of Patent:
November 16, 2021
Assignee:
MERCK PATENT GMBH
Inventors:
Dieter Dorsch, Mathilde Muzerelle, Lars Burgdorf, Margarita Wucherer-Plietker, Paul Czodrowski, Christina Esdar, Christos Tsaklakidis
Abstract: The present invention relates to compacted glycine granules, where at least 75% of the granules have a particle size of above 0.7 mm, and to a process for the preparation and use of granules of this type.
Type:
Grant
Filed:
January 24, 2017
Date of Patent:
November 16, 2021
Assignee:
Merck Patent GmbH
Inventors:
Harald Benk, Gudrun Birk, Melina Decker, Dieter Lubda, Guenter Moddelmog, Harald Muessig, Tanino Scaramuzza, Michael Schleehahn
Abstract: The present invention provides genetic markers on human chromosome 1 that are associated with a beneficial response to CRTH2 receptor antagonists. These CRTH2 receptor antagonist response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with CRTH2 receptor antagonist compositions and drug products, in methods of treating patients having a disease susceptible to treatment with a CRTH2 receptor antagonist, and in methods for selecting the most appropriate therapy for such patients.
Type:
Application
Filed:
July 16, 2021
Publication date:
November 11, 2021
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Gregory J. Opiteck, Peggy H. Wong, Joshua McElwee, Devan V. Mehrotra, Steven Greenberg, Zifang Guo
Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.
Type:
Application
Filed:
July 26, 2021
Publication date:
November 11, 2021
Applicant:
MERCK SHARP & DOHME CORP.
Inventors:
John P. CALDWELL, Reynalda DE JESUS, Fa-Xiang DING, Charles J. GIll, Ginny Dai HO, Sookhee N. HA, Sandra J. KOSEOGLU, Marc A. LABROLI, Sang Ho LEE, Christina MADSEN-DUGGAN, Mihir MANDAL, Terry ROEMER, Jing SU, Christopher Michael TAN, Zheng TAN, Haifeng TANG, Hao WANG, Christine YANG, Shu-Wei YANG
Abstract: The present invention relates to polymerisable compounds, to processes and intermediates for the preparation thereof, to liquid-crystal (LC) media comprising them, and to the use of the polymerisable compounds and LC media for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the polymer sustained alignment type.
Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.
Type:
Application
Filed:
July 26, 2021
Publication date:
November 11, 2021
Applicant:
MERCK SHARP & DOHME CORP.
Inventors:
John P. CALDWELL, Ginny Dai HO, Sookhee N. HA, Sandra J. KOSEOGLU, Marc A. LABROLI, Sang Ho LEE, Christina MADSEN-DUGGAN, Mihir MANDAL, Jianping PAN, Weidong PAN, Terry ROEMER, Jing SU, Christopher Michael TAN, Zheng TAN, Hao WANG, Christine YANG, Shu-Wei YANG
Abstract: The present invention relates to dosing regimens of an anti-LAG3 antibody useful for the treatment of cancer. In particular, the invention relates to the dosing regimen in a combination therapy which comprises administering an antibody of a Programmed Death 1 protein (PD-1) or Programmed Death Ligand 1 (PD-L1) and an antibody of Lymphocyte-Activation Gene 3 (LAG3). The invention also provides a method for treating cancer in a patient comprising administering to the patient an anti-LAG3 antibody and an anti-PD-1 antibody, wherein the tumor tissue section of the patient is PD-L 1 expression positive, and optionally LAG3 expression positive.
Type:
Application
Filed:
November 4, 2019
Publication date:
November 11, 2021
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Anson Kunjachan Abraham, Elliot K. Chartash, Kenneth Emancipator, Rosario Garrido, Jane Anne Healy, Jonathan W. Juco, Diane Levitan, Qing Zhao
Abstract: The present invention relates to liquid crystalline media comprising one or more benzothiadiazol derivatives of formula I, in which R11, R12, A11, A12, A21, A22, Z11, Z12, Z21, Z22, W, X11, X12, r and s have the meanings indicated in claim 1, to the use of such liquid crystal media for optical, electro-optical and electronic purposes, in particular in devices for regulating the passage of energy from an outside space into an inside space, for example in windows.
Type:
Grant
Filed:
July 17, 2017
Date of Patent:
November 9, 2021
Assignee:
Merck Patent GmbH
Inventors:
Peer Kirsch, Andreas Ruhl, Michael Junge, Ursula Patwal, Mila Fischer
Abstract: The present invention relates to formulations for the preparation of organic electronic devices (OLEDs) which comprise (A) at least one specific ester solvent containing an aromatic group and (B) at least one organic functional material selected from organic conductors, organic semiconductors, organic fluorescent compounds, organic phosphorescent compounds, organic light-absorbent compounds, organic light-sensitive compounds, organic photosensitisation agents and other organic photoactive compounds, selected from organometallic complexes of transition metals, rare earth metals, lanthanides and actinides.
Type:
Grant
Filed:
November 15, 2016
Date of Patent:
November 9, 2021
Assignee:
Merck Patent GmbH
Inventors:
Gaëlle Béalle, Christoph Leonhard, Hsin-Rong Tseng, Irina Martynova, Aurélie Ludemann, Edgar Kluge, Anja Jatsch, Manuel Hamburger, Li Wei Tan, Pawel Miskiewicz, Philip Edward May, Daniel Walker
Abstract: A liquid-crystalline medium, preferably having a nematic phase and dielectric anisotropy of 0.5 or more, which comprises one or more compounds of formula T in which denotes and the use thereof in an electro-optical display, particularly in an active-matrix display based on the IPS or FFS effect, to displays of this type which contain a liquid-crystalline medium of this type, and to the compounds of formula T and their use for the improvement of the transmission and/or response times of a liquid-crystalline medium which contains one or more additional mesogenic compounds.
Type:
Grant
Filed:
July 11, 2019
Date of Patent:
November 9, 2021
Assignee:
Merck Patent GmbH
Inventors:
Atsutaka Manabe, Constanze Brocke, Sven Baran, Sebastian Hofmeyer, Alexander Hahn
Abstract: The present invention relates to a novel directly compressible matrix for the production of tablets which disintegrate rapidly in the presence of moisture, in particular in the mouth.
Abstract: The present invention relates to a remover composition comprising, tetraalkylammonium hydroxide, a benzylic alcohol, a glycol component comprising at least one glycol compound, and a and an alkyl amine component, wherein said alkyl amine component is selected from the group consisting of a dialkyl amine, a mono-alkyl amine having structure having structure (I), and combinations thereof wherein, in said di-alkyl amine, one of the alkyl groups is a C-1 to C-4 n-alkyl and the other alkyl group is a C-16 to C-20 n-alkyl, and for said mono-alkyl amine m? and m are independently chosen from an integer ranging from 4 to 8. This invention also pertains to the process of using these compositions to remove a patterned photoresist from a substrate.
Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
Type:
Grant
Filed:
May 17, 2019
Date of Patent:
November 9, 2021
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick